Fujifilm Holdings Corporation

What does Fujifilm own?
Fujifilm owns a portfolio of brands across healthcare, electronics, imaging, and business innovation. Major brands include Fujifilm X Series and GFX Series (digital cameras), Instax (instant cameras), FUJIFILM Business Innovation (office equipment, formerly Fuji Xerox), Fujifilm Medical Systems (endoscopes and diagnostics), Fujifilm Bio CDMO (biopharmaceutical manufacturing), Toyama Chemical (pharmaceuticals), and Fujifilm Semiconductor Materials. The group comprises 270 consolidated subsidiaries as of March 2025.

Is Fujifilm publicly traded?
Yes. Fujifilm Holdings Corporation is publicly traded on the Tokyo Stock Exchange under ticker 4901. The company is a constituent of the Nikkei 225 and TOPIX indices. It has been publicly traded since its listing on the Tokyo Stock Exchange and is one of Japan's largest publicly traded companies by market capitalization.

Who founded Fujifilm?
Fujifilm was founded on January 20, 1934, as a spin-off from Dainippon Celluloid Company Limited (now Daicel Corporation). Dainippon Celluloid, founded in 1919 by Mokichi Morita, established Fuji Photo Film Co., Ltd. as a separate company to pursue photographic film manufacturing, which had been identified as a growth area for celluloid applications. The company was created as part of a Japanese government plan to establish a domestic photographic film industry.

Where is Fujifilm headquartered?
Fujifilm Holdings Corporation is headquartered in Minato, Tokyo, Japan, at the Tokyo Midtown Office, 7-3, Akasaka 9-chome, Minato-ku, Tokyo 107-0052. The company also maintains a Nishiazabu Office in Minato-ku. Fujifilm has maintained its headquarters in Tokyo since its founding and operates manufacturing and research facilities worldwide, including its historic Ashigara factory in Minamiashigara, Kanagawa Prefecture.

What is Fujifilm's revenue?
Fujifilm reported consolidated revenue of 3,195.8 billion yen (approximately 3.20 trillion yen, or roughly $21 billion at fiscal 2025 exchange rates) for fiscal year 2025 (the year ended March 31, 2025). Operating income was 330.2 billion yen, and net income attributable to Fujifilm Holdings was 261.0 billion yen. Revenue grew 7.9% year-over-year, driven by the Electronics and Imaging segments.

Does Fujifilm still make film?
Yes. Fujifilm continues to manufacture photographic film, including color negative film, color reversal (slide) film, and instant film for Instax cameras. While film sales are a small fraction of total company revenue, the film business has experienced a resurgence in the 2020s as analog photography has grown in popularity among younger consumers. Fujifilm is one of the few major manufacturers still producing photographic film, alongside Kodak and Ilford.

What is Fujifilm's largest business segment?
Healthcare is Fujifilm's largest business segment by revenue, generating 1,022.6 billion yen in fiscal 2025. The segment includes medical systems (endoscopes, diagnostic imaging, in-vitro diagnostics), the Bio CDMO biopharmaceutical manufacturing business, pharmaceuticals, and regenerative medicine. Business Innovation is the second-largest segment at 1,198.5 billion yen, followed by Electronics at 432.8 billion yen and Imaging at 542.0 billion yen.

Fuji Photo Film Co., Ltd. was established on January 20, 1934, as a spin-off from Dainippon Celluloid Company Limited (now Daicel Corporation). Dainippon Celluloid, founded in 1919 by Mokichi Morita through the merger of eight celluloid companies, had begun researching photographic film as a new application for celluloid in the 1920s. The Japanese government adopted domestic film production as a subsidized project in 1933, and Dainippon Celluloid decided to establish a separate company to pursue the photographic film business. Fuji Photo Film inherited the split-off photographic film operations and was established as an integrated manufacturer of photosensitive materials.

The company's early years were difficult. Fuji Photo Film faced quality challenges and intense competition from Eastman Kodak and Agfa, which dominated the global film market. Through the efforts of researchers including Sakae Haruki, the company improved its film quality and was adopted by Japanese film distributors within approximately two years of founding. The company built its Ashigara factory in Minamiashigara, Kanagawa Prefecture, in 1933, which served as the production base for the new company.

In 1936, Fuji Photo Film launched its first independently developed products, including medical X-ray films. The company expanded through the 1940s and 1950s, constructing additional production facilities and broadening its product range to include motion picture films, graphic arts films, and photographic paper. The company became the dominant photographic film manufacturer in Japan and began expanding internationally in the 1960s, establishing subsidiaries in the United States and Europe.

The 1970s and 1980s marked Fuji Photo Film's global expansion. The company competed directly with Kodak in the consumer film market, gaining significant market share in the United States and Europe. Fuji film became known for its color reproduction characteristics, which many photographers preferred over Kodak's. The company sponsored the 1984 Los Angeles Olympics, which increased its brand visibility in the United States. By the late 1980s, Fuji Photo Film held approximately 40% of the global photographic film market.

The transition to digital photography in the 1990s and 2000s posed an existential threat to the company. Film sales began declining sharply in the early 2000s as digital cameras replaced film cameras. Unlike Kodak, which was slow to adapt and filed for bankruptcy in 2012, Fujifilm's management under CEO Shigetaka Komori launched an aggressive diversification strategy beginning in 2000. Komori identified six growth areas where Fujifilm's core technologies could be applied: healthcare, life sciences, document systems, optical devices, highly functional materials, and digital imaging.

The diversification strategy involved approximately 40 acquisitions and strategic investments between 2000 and 2010. Key moves included the acquisition of Toyama Chemical (pharmaceuticals) in 2006, the purchase of IBM's microelectronics materials business, and investments in regenerative medicine through iPS cell technology partnerships. The company also expanded its medical systems business, becoming a major manufacturer of endoscopes, diagnostic imaging equipment, and in-vitro diagnostics.

In 2006, the company acquired the photographic film business of UK-based Ilford, and in 2012, it acquired the inkjet business of Dimatix. The company changed its name from Fuji Photo Film Co., Ltd. to FUJIFILM Holdings Corporation in 2006 as part of a transition to a holding company structure. FUJIFILM Corporation was established as the main operating company under the holding structure.

The healthcare transformation accelerated in the 2010s. In 2015, Fujifilm acquired Cellular Dynamics International, a leader in induced pluripotent stem (iPS) cell technology, for approximately $309 million. In 2019, the company acquired Biogen's stake in Fujifilm Diosynth Biotechnologies and expanded its Bio CDMO business. In 2020, Fujifilm announced a $2 billion investment to expand its Bi CDMO operations, including a large-scale biopharmaceutical manufacturing facility in Denmark acquired from Biogen.

The Imaging segment, which includes digital cameras, has experienced a revival in the 2020s. Fujifilm's X Series of APS-C mirrorless cameras and GFX Series of medium format mirrorless cameras have been commercially successful, particularly among enthusiasts who value the company's film simulation color profiles. The Instax instant camera line has also been a strong seller, especially among younger consumers. The Imaging segment reported revenue of 542.0 billion yen in fiscal 2025, up 15.4% year-over-year, driven by strong sales of Instax and the X and GFX camera series.

In 2025, Fujifilm launched the GFX100RF, a fixed-lens medium format camera with a 102-megapixel sensor, and the GFX ETERNA 55, a filmmaking camera using a large-format sensor. The company also introduced the X-M5, an APS-C compact system camera that received the TIPA World Award for Best Compact System Camera in 2025. At CP+ 2026 in Yokohama, Fujifilm executives confirmed that the GFX100RF would not be a single-edition model and that the company was developing additional products in the "RF line" of medium format compacts.

Fujifilm has established sustainability targets through its Sustainable Value Plan 2030 (SVP2030), which identifies priority issues including climate change, resource efficiency, product safety, and supply chain responsibility. The company has set science-based targets for greenhouse gas emissions reduction covering Scope 1, 2, and 3 emissions, and aims to achieve net-zero emissions from its operations by 2040.

The company's environmental initiatives include reducing carbon emissions from manufacturing, increasing renewable energy use, developing environmentally conscious products, and promoting recycling. Fujifilm has invested in renewable energy installations at its manufacturing facilities and has set a target of achieving 50% renewable electricity for the Fujifilm Group by 2030. The company publishes an annual Sustainability Report detailing its environmental performance, including energy consumption, emissions, water use, and waste management data.

On social responsibility, Fujifilm maintains programs focused on healthcare access, education, and community development. The company has initiatives to improve healthcare in developing countries through its medical equipment and diagnostic products. Fujifilm also supports photography education and cultural preservation through its photography-related programs and museum partnerships.

For ethical business practices, Fujifilm maintains compliance programs covering supply chain management, data privacy, anti-corruption, and corporate governance. The company publishes a Sustainability Data Book annually and has obtained independent assurance for selected environmental and social data. Fujifilm has not faced major ESG-related controversies as of August 2026, though the company's pharmaceutical operations are subject to regulatory oversight by the FDA, EMA, and other health authorities.

Fujifilm has received recognition across its business segments:

• Imaging: The Fujifilm GFX100RF received the TIPA World Award for Best Medium Format Camera in 2025, and the Fujifilm X-M5 received the TIPA World Award for Best Compact System Camera in 2025. These awards are independently judged by the Technical Image Press Association.
• Healthcare: Fujifilm's medical systems products have received recognition for innovation in endoscopy and diagnostic imaging, including awards from radiology and gastroenterology professional societies.
• Corporate: Fujifilm has been included in major sustainability indices including the Dow Jones Sustainability World Index and the FTSE4Good Global Index, reflecting its environmental, social, and governance performance.
• Design: Fujifilm camera products have received design awards from the Red Dot Design Awards and iF Design Awards for industrial design and user interface innovation.

Fujifilm has faced several controversies and regulatory challenges:

Fuji Xerox Accounting Scandal (2017): Fuji Xerox Co., Ltd. (now FUJIFILM Business Innovation) was found to have improperly recognized approximately 37.5 billion yen in revenue across multiple fiscal years at its New Zealand and Australian subsidiaries. The accounting irregularities involved inflated revenue from office equipment leasing contracts. The scandal led to the resignation of senior executives and a review of governance practices across the Fuji Xerox group. The company restated its financial results and implemented strengthened internal controls. The incident damaged Fujifilm's reputation for corporate governance and delayed strategic decisions regarding the Fuji Xerox joint venture.

Fujifilm Xerox Xerox Merger Failure (2018): Fujifilm attempted to merge with Xerox Corporation in 2018 through a complex transaction that would have combined the two companies. The deal was blocked by Xerox shareholders, including activist investors Carl Icahn and Darwin Deason, who argued that the merger terms undervalued Xerox. The failed merger led to litigation and eventually to Fujifilm acquiring Xerox's 25% stake in Fuji Xerox in 2021 for approximately $2.3 billion, making it a wholly-owned subsidiary renamed FUJIFILM Business Innovation.

Avigan Drug Controversy (2020-2021): Fujifilm's antiviral drug Avigan (favipiravir) was promoted as a potential treatment for COVID-19 during the pandemic. The Japanese government invested in Avigan development and stockpiling. However, clinical trial results were mixed, and the drug did not receive widespread international regulatory approval. Critics questioned the Japanese government's investment in Avigan and whether political considerations influenced the drug's promotion. Fujifilm received government funding for Avigan development, which drew scrutiny about the relationship between the company and government health policy.

Pharmaceutical Regulatory Oversight: As a pharmaceutical manufacturer through Toyama Chemical and the Bio CDMO business, Fujifilm is subject to regulatory oversight by the FDA, EMA, PMDA (Japan), and other health authorities. Manufacturing facilities have undergone inspections and received standard regulatory observations, though no major enforcement actions have been publicized as of August 2026.